FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283259124> ?p ?o ?g. }

• W4283259124 endingPage "617" @default.
• W4283259124 startingPage "610" @default.
• W4283259124 abstract "Patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) who achieve progression-free survival (PFS) at 24 months (PFS24) after immunochemotherapy (IC) have excellent overall survival (OS) comparable to that of the age- and sex-matched general population. However, a similar landmark has not been established for patients with relapsed or refractory (RR) DLBCL following frontline IC who are subsequently treated with salvage therapy followed by autologous stem cell transplantation (ASCT). To evaluate the role of PFS24 as a landmark after ASCT in patients with RR DLBCL, we identified patients with RR DLBCL after frontline R-CHOP or R-CHOP-like IC who underwent salvage therapy and ASCT at Mayo Clinic between July 2000 and December 2017 and University of Iowa between April 2003 and April 2020 from institutional lymphoma and transplantation databases. Clinical characteristics, treatment information, and outcome data were abstracted. PFS, OS, and post-ASCT relapse survival (PRS) were analyzed using Kaplan-Meier method, and cumulative incidences of relapse versus nonrelapse mortality and different causes of death were compared accounting for competing events. A total of 437 patients were identified. Median age at ASCT was 61 years (range 19-78), and 280 (64%) were male. After a median post-ASCT follow-up of 8.0 years (95% confidence interval [CI], 7.2-8.7), 215 patients had a relapse (or disease progression), 180 within 2 years and 35 after 2 years. For the entire cohort, the post-ASCT relapse rate was much higher than the nonrelapse mortality rate (48.1% versus 9.1% at 5 years). Median PFS and OS after ASCT was 2.7 and 5.4 years, respectively. Lymphoma was the primary cause of death after ASCT. In contrast, for patients who had achieved PFS24 (n = 220), rates of post-PFS24 relapse and nonrelapse mortality were similar (14.8% and 12.3% at 5 years). Median PFS and OS after achieving PFS24 was 10.0 and 11.5 years, respectively. Lymphoma-related and -unrelated death rates were similar after achieving PFS24. For all patients who had a post-ASCT relapse, median PRS was 0.7 (95% CI, 0.5-0.9) year, and late relapse (>2 versus ≤2 years after ASCT) was associated with better PRS (median 2.3 [1.7-4.8] versus 0.5 [0.3-0.7] years, P< .001). The study establishes PFS24 as an important landmark associated with post-ASCT outcomes in patients with RR DLBCL after frontline IC." @default.
• W4283259124 created "2022-06-23" @default.
• W4283259124 creator A5008583422 @default.
• W4283259124 creator A5010322304 @default.
• W4283259124 creator A5017327825 @default.
• W4283259124 creator A5025688165 @default.
• W4283259124 creator A5038008601 @default.
• W4283259124 creator A5038585259 @default.
• W4283259124 creator A5043341277 @default.
• W4283259124 creator A5048644166 @default.
• W4283259124 creator A5051399808 @default.
• W4283259124 creator A5059729547 @default.
• W4283259124 creator A5061713890 @default.
• W4283259124 creator A5064206924 @default.
• W4283259124 creator A5071201232 @default.
• W4283259124 creator A5074827009 @default.
• W4283259124 creator A5076892547 @default.
• W4283259124 date "2022-09-01" @default.
• W4283259124 modified "2023-09-27" @default.
• W4283259124 title "Progression-Free Survival at 24 Months as A Landmark After Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B-cell Lymphoma" @default.
• W4283259124 cites W1510476229 @default.
• W4283259124 cites W1799746163 @default.
• W4283259124 cites W1969582706 @default.
• W4283259124 cites W1971955856 @default.
• W4283259124 cites W2018071905 @default.
• W4283259124 cites W2058015212 @default.
• W4283259124 cites W2133345449 @default.
• W4283259124 cites W2137266530 @default.
• W4283259124 cites W2138786695 @default.
• W4283259124 cites W2145304413 @default.
• W4283259124 cites W2145453495 @default.
• W4283259124 cites W2150587745 @default.
• W4283259124 cites W2153665789 @default.
• W4283259124 cites W2167556523 @default.
• W4283259124 cites W2168205543 @default.
• W4283259124 cites W2172003817 @default.
• W4283259124 cites W2285589106 @default.
• W4283259124 cites W2514876338 @default.
• W4283259124 cites W2577385476 @default.
• W4283259124 cites W2729210473 @default.
• W4283259124 cites W2744261860 @default.
• W4283259124 cites W2767762193 @default.
• W4283259124 cites W2773804840 @default.
• W4283259124 cites W2807744826 @default.
• W4283259124 cites W2903062212 @default.
• W4283259124 cites W2948321946 @default.
• W4283259124 cites W2988084431 @default.
• W4283259124 cites W2997230455 @default.
• W4283259124 cites W3022476818 @default.
• W4283259124 cites W3082855561 @default.
• W4283259124 cites W3212349863 @default.
• W4283259124 cites W4200014243 @default.
• W4283259124 cites W4200201081 @default.
• W4283259124 doi "https://doi.org/10.1016/j.jtct.2022.06.015" @default.
• W4283259124 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35752441" @default.
• W4283259124 hasPublicationYear "2022" @default.
• W4283259124 type Work @default.
• W4283259124 citedByCount "5" @default.
• W4283259124 countsByYear W42832591242022 @default.
• W4283259124 countsByYear W42832591242023 @default.
• W4283259124 crossrefType "journal-article" @default.
• W4283259124 hasAuthorship W4283259124A5008583422 @default.
• W4283259124 hasAuthorship W4283259124A5010322304 @default.
• W4283259124 hasAuthorship W4283259124A5017327825 @default.
• W4283259124 hasAuthorship W4283259124A5025688165 @default.
• W4283259124 hasAuthorship W4283259124A5038008601 @default.
• W4283259124 hasAuthorship W4283259124A5038585259 @default.
• W4283259124 hasAuthorship W4283259124A5043341277 @default.
• W4283259124 hasAuthorship W4283259124A5048644166 @default.
• W4283259124 hasAuthorship W4283259124A5051399808 @default.
• W4283259124 hasAuthorship W4283259124A5059729547 @default.
• W4283259124 hasAuthorship W4283259124A5061713890 @default.
• W4283259124 hasAuthorship W4283259124A5064206924 @default.
• W4283259124 hasAuthorship W4283259124A5071201232 @default.
• W4283259124 hasAuthorship W4283259124A5074827009 @default.
• W4283259124 hasAuthorship W4283259124A5076892547 @default.
• W4283259124 hasConcept C126322002 @default.
• W4283259124 hasConcept C141071460 @default.
• W4283259124 hasConcept C143998085 @default.
• W4283259124 hasConcept C2776694085 @default.
• W4283259124 hasConcept C2778559949 @default.
• W4283259124 hasConcept C2779050716 @default.
• W4283259124 hasConcept C2779338263 @default.
• W4283259124 hasConcept C2779725641 @default.
• W4283259124 hasConcept C2780739268 @default.
• W4283259124 hasConcept C2780775027 @default.
• W4283259124 hasConcept C2908647359 @default.
• W4283259124 hasConcept C2911091166 @default.
• W4283259124 hasConcept C71924100 @default.
• W4283259124 hasConcept C72563966 @default.
• W4283259124 hasConcept C99454951 @default.
• W4283259124 hasConceptScore W4283259124C126322002 @default.
• W4283259124 hasConceptScore W4283259124C141071460 @default.
• W4283259124 hasConceptScore W4283259124C143998085 @default.
• W4283259124 hasConceptScore W4283259124C2776694085 @default.
• W4283259124 hasConceptScore W4283259124C2778559949 @default.
• W4283259124 hasConceptScore W4283259124C2779050716 @default.
• W4283259124 hasConceptScore W4283259124C2779338263 @default.

• next